Unanswered questions in acute myeloid leukaemia (Q35824988)

10 August 2017

1 reference

title

Unanswered questions in acute myeloid leukaemia (English)

1 reference

10 August 2017

1 reference

Felicetto Ferrara

1

1 reference

10 August 2017

1 July 2004

1 reference

Lancet Oncology Commission

10 August 2017

1 reference

10 August 2017

5

1 reference

10 August 2017

7

1 reference

10 August 2017

443-450

1 reference

Hematopoietic growth factors and the future of therapeutic research on acute myeloid leukemia

10 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Prognostic factors in acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Prognostic factors in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Molecular characterization of acute leukemias by use of microarray technology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Management of acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Approaches to induction therapy with adult acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Complete remission induced by G-CSF in a patient with acute myeloid leukemia with t(8;21)(q22;q22)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Complete remission in acute myeloid leukaemia with t(8;21) following treatment with G-CSF: flow cytometric analysis of in vivo and in vitro effects on cell maturation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Treatment of acute myeloid leukaemia in younger patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--an adult treater's view

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--a statistician's view

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Ad

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Autologous stem cell transplantation for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Autologous stem cell transplantation for adult acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

High-dose cytarabine as consolidation treatment for patients with acute myeloid leukemia with t(8;21).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

High-dose idarubicin and busulphan as conditioning for autologous stem cell transplantation in acute myeloid leukemia: a feasibility study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Flt3 mutations and leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

The role of FLT3 in haematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Acute myeloid leukemia in the elderly: biology and therapeutic strategies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Acute myeloid leukemia in the elderly: a critical review of therapeutic approaches and appraisal of results of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: importance of the source of stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

A modular questionnaire for the assessment of longterm quality of life in leukaemia patients: the MRC/EORTC QLQ-LEU.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901512-8

7 January 2021

10.1016/S1470-2045(04)01512-8

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15231251